FDA Panel Recommends Device for Depression
Experts Want Device Restricted to Most Severely Ill Patients
June 16, 2004 -- An FDA advisory panel has tentatively recommended that the FDA approve an implantable electrical nerve stimulator device to treat severe depression.
But committee's 5-2 vote for FDA approval hinged on several conditions, including restricting the device to patients with severe depression who have not responded to other treatments.
The device has been used since 1997 to treat patients with treatment-resistant epilepsy. Since then, more than 22,000 patients have received the implanted device, called vagus nerve stimulation (VNS), according to the company.
Cyberonics Inc., the device's manufacturer, asked advisors to recommend the FDA's go-ahead for the device in light of studies suggesting that it can help ease depression in some patients who use it for one to two years. Cyberonics is a WebMD sponsor.
VNS consists of a pacemaker-like device the size of a stopwatch that a surgeon implants in a patient's upper chest. Wires attach the device to the vagus nerve, which runs from the neck into the brain. It's thought that the vagus nerve provides electrical impulses to areas of the brain believed to be important in regulating mood. The device is implanted during a surgical procedure; the recipient can usually go home the same day.
Once implanted, the device delivers electrical pulses to the vagus nerve every few seconds, thereby stimulating the brain. The company says it intends the device only for adult patients with severe depression that has not improved after treatment with antidepressant drugs.
Data submitted by Cyberonics showed little improvement in depression symptoms after patients used the device for three months. But company officials point to data showing that 18 of 59 patients showed at least a 50% improvement in depression after one year of use. Twenty-five out of the 59 showed improvements after two years.
Officials argue that the improvements are especially beneficial since many severely depressed patients fail to reliably take medication and often do not show long-term improvements with antidepressant drugs.
"This alone I think is a significant benefit of VNS therapy," says Richard J. Rudolph, MD, Cyberonics' chief medical officer.